Phyllanthostatin IAlternative Names: NSC 328426; Phyllanthoside; Phyllanthostatin
Latest Information Update: 26 Oct 1994
At a glance
- Originator National Cancer Institute (USA)
- Class Antineoplastics; Antivirals
- Mechanism of Action DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Oct 1994 NSC 328426's new name is phyllanthostatin I.